[带运动对患有下值抑郁症的患者肠道菌群的影响]
Ziru Yu1, Jin Xian2, Ling Wang1
1College of Acupuncture-Moxibustion and Tuina, Shandong University of TCM, Jinan 250014, China.
Zhongguo zhen jiu = Chinese acupuncture & moxibustion
|August 7, 2024
概括
带性催化疗有效地通过改善肠道菌群多样性来治疗下值抑郁症 (SD). 这种疗法增加了有益细菌,减少了有害细菌,为SD管理提供了一种新的方法.
科学领域:
- 综合医学是一个整体的医学.
- 微生物组研究 微生物组研究
- 心理健康 心理健康
背景情况:
- 低于值的抑郁症 (SD) 是一个重大的临床挑战.
- 肠道微生物群失调症越来越多地与各种心理健康状况有关,包括抑郁症.
- 了解肠-大脑轴为SD提供了潜在的治疗点.
研究的目的:
- 为了评估腹动摇治疗值以下抑郁症 (SD) 的临床有效性.
- 为了研究带塞对SD患者肠道菌群的影响.
- 探索在SD.中带运动治疗效果背后的潜在机制.
主要方法:
- 一个随机对照试验设计,涉及36名SD患者和36名健康对照.
- SD患者每周接受8次带运动.
- 临床疗效使用汉密尔顿抑郁量表17项 (HAMD-17) 和流行病学研究中心抑郁量表 (CES-D) 评分进行评估.
- 使用16S rRNA测序技术对治疗前后收集的便样本进行了肠道菌群组成分析.
主要成果:
- 在SD患者中,腹性催化剂显著降低了HAMD-17和CES-D得分 (P<0.05),总有效率为90.9%.
- 与对照组相比,SD患者的微生物多样性 (Sobs,Shannon,Ace指数) 减少,Escherichia-Shigella丰度增加.
- 治疗调节了肠道菌群,减少了Escherichia-Shigella,增加了像Ruminococcus和Christensenellaceae-R群这样的有益细菌,这与改善的抑郁症得分相关.
结论:
- 低于值的抑郁症与肠道菌群失调有关.
- 带性催化剂在治疗SD方面表现出显著的临床疗效.
- 治疗机制可能涉及肠道菌群的丰富性和多样性的调节,促进有益细菌和减少有害的细菌.
关键词:
16S rRNA 是一个16S rRNA.抑郁 抑郁症 抑郁症 抑郁症 是一种肠道菌群是指肠道上的植物.在值以下的抑郁症.带运动 (Umbilical Moxibustion) 是一种带运动.更多相关视频
05:19Author Spotlight: An Effective Traditional Chinese Medicinal Treatment for Chronic Obstructive Pulmonary Disease with Abdominal Distension
Published on: September 1, 2023
1.4K
05:36Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
Published on: October 4, 2024
485
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
189
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
189
01:17Irritable Bowel Syndrome I: Introduction
264
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
264